|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.52 CHF | +0.85% |
|
-1.07% | +14.43% |
| 08-05 | Sandoz gains on strong biosimilar growth, touts 'golden decade' | RE |
| 08-04 | Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31 | DJ |
| Market Cap | 293B 254B 237B 218B 411B 27,861B 415B 2,780B 1,091B 13,940B 1,100B 1,076B 46,169B | P/E 2026 * |
21.9x | P/E 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise Value | 326B 282B 263B 242B 457B 31,010B 462B 3,094B 1,214B 15,516B 1,225B 1,198B 51,387B | EV / Sales 2026 * |
5.66x | EV / Sales 2027 * | 5.25x |
| Free-Float |
91.66% | Yield 2026 * |
2.83% | Yield 2027 * | 2.96% |
Last Transcript: Novartis AG
| 1 day | +0.84% | ||
| 1 week | -1.07% | ||
| Current month | -0.93% | ||
| 1 month | +0.26% | ||
| 3 months | +8.46% | ||
| 6 months | +4.55% | ||
| Current year | +14.43% |
| 1 week | 124 |  | 128.36 |
| 1 month | 121.06 | | 131.5 |
| Current year | 107.68 | | 131.5 |
| 1 year | 91.56 | | 131.5 |
| 3 years | 81.1 | | 131.5 |
| 5 years | 72.84 | | 131.5 |
| 10 years | 65.09 | | 131.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Karen Hale
CMP | Compliance Officer | 58 | 14/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/17/26 A | Sell | 30,743 | 0.0015% | |||
| 2/10/26 A | Sell | 7,500 | 0.0004% | |||
| 2/9/26 A | Sell | 67,000 | 0.0032% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.85% | -1.07% | +35.78% | +39.59% | 293B | |
| +4.86% | -3.32% | +52.73% | +160.26% | 1,043B | |
| +1.04% | -2.99% | +50.87% | +52.38% | 621B | |
| +0.98% | -6.49% | +24.00% | +66.66% | 435B | |
| +0.56% | +3.51% | +47.14% | +38.12% | 361B | |
| +0.16% | -5.22% | +9.06% | +10.75% | 251B | |
| +4.57% | +5.21% | +35.91% | +67.64% | 220B | |
| +1.85% | -9.10% | +3.90% | -44.88% | 201B | |
| -2.58% | -0.73% | +17.16% | +67.46% | 164B | |
| +1.57% | +2.62% | +4.28% | -26.30% | 147B | |
| Average | +1.09% | -3.37% | +28.08% | +43.17% | 373.62B | |
| Weighted average by Cap. | +1.07% | -3.61% | +37.18% | +72.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.58B 49.87B 46.49B 42.76B 80.72B 5,475B 81.63B 546B 214B 2,740B 216B 212B 9,074B | 61.12B 52.94B 49.35B 45.39B 85.68B 5,812B 86.64B 580B 228B 2,908B 230B 225B 9,631B |
| Net income | 13.78B 11.94B 11.13B 10.23B 19.32B 1,310B 19.53B 131B 51.31B 656B 51.76B 50.62B 2,171B | 15.36B 13.3B 12.4B 11.4B 21.53B 1,460B 21.77B 146B 57.19B 731B 57.68B 56.41B 2,420B |
| Net Debt | 33.11B 28.68B 26.74B 24.59B 46.42B 3,149B 46.94B 314B 123B 1,575B 124B 122B 5,218B | 27.82B 24.09B 22.46B 20.66B 39B 2,645B 39.43B 264B 104B 1,323B 104B 102B 4,383B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/08/26 | CHF 125.42 | +0.77% | 448,819 |
| 05/08/26 | CHF 124.46 | -0.11% | 1,877,929 |
| 04/08/26 | CHF 124.60 | +0.08% | 2,417,668 |
| 03/08/26 | CHF 124.50 | -1.66% | 2,482,307 |
| 31/07/26 | CHF 126.60 | -0.14% | 2,230,428 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
